MARKET RELEASE
Cryosite Limited (ASX: CTE)
21 September 2026

Annual General Meeting Notice of Meeting

Cryosite Limited (ACN 090 919 476) (ASX: CTE) (**Cryosite** or **Company**) advises the Annual General Meeting of Shareholders of the Company will be held on Thursday 22 October 2026 at 11:00am AEDT at Thomson's offices at Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3004.

In accordance with the Corporations Act 2001 (Cth) (Act) in relation to electronic notice of meetings, the Notice of Meeting (**Notice**) is being made available to Shareholders electronically and can be viewed and downloaded from:

- The Company's website at: https://investorhub.cryosite.com/announcements; or
- The Company's ASX market announcements platform at www.asx.com.au (ASX:CTE)

Further instructions are set out in the Notice which is attached to this release.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

- Visit: www.automicgroup.com.au
- Email: hello@automic.com.au
- Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

Authorised for lodgement by the Board of the Company.

—END—

About Cryosite

Cryosite is a unique Australian company and a world-class specialist in providing outsourced clinical trial and biological depot services.

Established in 2000, Cryosite is highly experienced in clinical trial logistics. Our team is comprised of highly qualified scientists and clinical trials experts who ensure complex clinical trials are conducted with seamless efficiency and safety.

We manage the importation, receipt, storage, distribution and reverse logistics of specialised ambient, cold, frozen, ultra-frozen, liquid nitrogen clinical trial, pharmaceutical and biological products. Cryosite's third party depot services are professional, reliable and compliant; our people are experts in their respective fields and are approachable, ethical and responsive to clients' needs.

To learn more, please visit our website or Cryosite's Investor Hub.

South Granville: Headquarters

- 13a Ferndell Street, South Granville, NSW, 2142
- Building Area: ~1,800sqm
- GMP, GWP licensed
- Services include Clinical Trial and Biological:
    - Storage
    - Importation
    - Receipt
    - Labelling
    - Distribution
    - Secondary packaging
    - Reverse logistics
    - Expiry extension

Auburn: Secondary Facility

- 100-104 Adderley Street West, Auburn, NSW, 2144
- ~15 minutes' drive from South Granville
- Building Area: ~2,100sqm (clearance 9.1m)
- Services include:
    - Clinical Trial and Biological service expansion
    - Medical devices
    - Reverse logistics
    - Pallet storage
- Talk to us about your requirements - contact@cryosite.com

professional, dependable, compliant

All Registry communications to:
Automic
Group GPO
Box 5193
Sydney NSW 2001
Telephone (free call within Australia): 1300 288 664
ASX Code: CTE

<<EntityRegistrationDetailsLine1Envelope>>
<<EntityRegistrationDetailsLine2Envelope>>
<<EntityRegistrationDetailsLine3Envelope>>
<<EntityRegistrationDetailsLine4Envelope>>
<<EntityRegistrationDetailsLine5Envelope>>
<<EntityRegistrationDetailsLine6Envelope>>

21 September 2026

Upcoming Annual General Meeting of Shareholders

Dear Shareholder,

Cryosite Ltd ACN 090 919 476 (ASX: CTE or "the **Company**"), advises the 2026 Annual General Meeting will be held in person at Thomsons' offices at Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000 on Thursday 22 October 2026, at 11am (Melbourne time) (**Meeting**).

Notice of Meeting
The Notice of Meeting and Explanatory Memorandum (**Notice**) for the Meeting is available online and can be viewed and downloaded by shareholders of the Company (**Shareholders**) from the Company's website at https://investorhub.cryosite.com/announcements or the Company's ASX market announcements platform at www.asx.com.au (ASX: CTE)

In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws Amendment (2021 Measures No.1) Act 2021 (Cth), Shareholders will not be sent a hard copy of the Notice or Proxy Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy Form in hard copy.

Online scan the QR code below using your smartphone	Lodge the Proxy Form online at https://investor.automic.com.au/#/loginsah by following the instructions: 1. Login to the Automic website using the holding details as shown on the Proxy Form. 2. Click on 'View Meetings' – 'Vote'. To use the online lodgment facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown as shown at the top of your holding statement.

For further information on the online proxy lodgment process, or if you require a hard copy Proxy Form, please contact the Company's Share Registry, Automic Registry Services (**Automic**), at hello@automicgroup.com.au or via phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Shareholder queries in relation to the Meeting
Shareholders can contact the Company Secretary with any questions prior to the meeting via email at hamish.george@bio101.com

Copies of all Meeting related material including the Notice and the Company's Annual Report, are available to download from the Company's website and the Company's ASX market announcements platform. In the event it is necessary or appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders via the ASX and the Company's website.

Authorised for ASX release by the Company Secretary.

CRYOSITE LIMITED

ACN 090 919 476

NOTICE OF ANNUAL GENERAL MEETING

Notice is given that the Annual General Meeting (**AGM** or **Meeting**) of Shareholders of Cryosite Limited (**Cryosite** or the **Company**) will be held:

Date: Thursday, 22 October 2026

Time: 11.00am (Melbourne time)

Venue: Thomsons, Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000

The Explanatory Memorandum accompanying this Notice of Meeting provides additional information on matters to be considered at the AGM. The Explanatory Memorandum, the Entitlement to Attend and Vote Section and the Proxy Form are part of this Notice of Meeting.

The business of the Meeting is as follows:

A. CONSIDERATION OF REPORTS

To receive and consider the Company's Financial Report, the Directors' Report and the Independent Auditor's Report for the financial year ended 30 June 2026.

All Shareholders can view the Annual Report which contains the Annual Financial Report, the Directors' Report and the Independent Auditor's Report for the year ended 30 June 2026 on the Company's ASX page at: https://www.asx.com.au/markets/company/CTE

B. QUESTIONS AND COMMENTS

Following consideration of the Reports, the Chair will give Shareholders attending the Meeting a reasonable opportunity to ask questions about, or comment on, the Reports and the management of the Company.

The Chair will also give Shareholders a reasonable opportunity to ask the Company's Auditor questions relevant to:

a) the conduct of the audit;
b) the preparation and content of the Independent Auditor's Report;
c) the accounting policies adopted by the Company in relation to the preparation of the financial statements; and
d) the independence of the Auditor in relation to the conduct of the audit.

The Chair will also give the Auditor a reasonable opportunity to answer written questions submitted by Shareholders that are relevant to the content of the Independent Auditor's Report or the conduct of the audit.

All Shareholders present at the Meeting will have a reasonable opportunity to ask questions during the AGM.

Shareholders who prefer to register questions in advance of the AGM are invited to do so by emailing the Company Secretary at hamish.george@bio101.com.

To allow time to collate questions and prepare answers, please submit any questions by no later than 5.00pm (Melbourne time) on Thursday, 15 October 2026.

Questions received in advance of the AGM by email will be collated and, during the AGM, the Chair will seek to address as many of the more frequently raised topics as possible. However, there may not be sufficient time available at the AGM to address all topics raised. Please note that individual responses will not be sent to Shareholders.

C. ITEMS FOR APPROVAL

Resolution 1. Adoption of Remuneration Report

To consider and, if thought fit, to pass with or without amendment, the following as a **non–binding resolution**:

> ***"****That, for the purposes of section 250R(2) of the Corporations Act, the Company's Remuneration Report for the financial year ended 30 June 2026, as set out in the Directors' Report, is adopted."*

Please note that, in accordance with section 250R(3) of the Corporations Act, the vote on this resolution is advisory only and does not bind the Directors or the Company.

Voting Exclusion - Resolution 1

In accordance with section 250R of the Corporations Act, the Company will disregard any vote cast on this Resolution 1:

a) in any capacity by, or on behalf of, a member of the Key Management Personnel (**KMP**) whose remuneration details are included in the Remuneration Report; or

b) a Closely Related Party of such member,

unless the vote is cast as a proxy for a person entitled to vote:

a) and the proxy form specifies how the proxy is to vote; or

b) the proxy is the Chair of the meeting and the appointment of the Chair as proxy:

(i) does not specify the way the proxy is to vote on the Resolution; and

(ii) which expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a member of the KMP.

Resolution 2. Issue of Options – Mr. Andrew Kerr

To consider and, if thought fit, to pass with or without amendment the following resolution as an **ordinary resolution**:

> *"That for the purposes of ASX Listing Rule 10.11, sections 195(4) and 208 of the Corporations Act and for all other purposes, the Shareholders approve the issue of an aggregate of 666,667 unlisted options to Mr. Andrew Kerr (and/or his nominee(s)) as described in the Explanatory Memorandum which accompanies and forms part of this Notice of Meeting."*

Voting Exclusion - Resolution 2

The Company will disregard any votes cast in favour of this Resolution 2 by or on behalf of:

a) Mr. Andrew Kerr;

b) any other person who will obtain a material benefit as a result of the issue of the securities, except a benefit solely by reason of being a holder of ordinary securities in the Company; or

c) an associate of those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or

b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

c) a Shareholder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution, and

(ii) the Shareholder votes on the Resolution in accordance with directions given by the beneficiary to the Shareholder to vote in that way.

Voting Prohibition - Resolution 2

In accordance with section 250BD of the Corporations Act, a vote on this Resolution 2 must not be cast by a person appointed as a proxy, where that person is either a member of the KMP or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:

a) the person is appointed as a proxy and the appointment specifies how the proxy is to vote; or

b) the person appointed as proxy is the Chair and the appointment does not specify how the Chair is to vote but expressly authorises the Chair to exercise the proxy even if the Resolution is connected with the remuneration of a member of the KMP.

Resolution 3. Issue of Options – Mr. Scott Thomas

To consider and, if thought fit, to pass with or without amendment the following resolution as an **ordinary resolution**:

> *"That for the purposes of ASX Listing Rule 10.11, section 208 of the Corporations Act and for all other purposes, the Shareholders approve the issue of an aggregate of 666,667 unlisted options to Mr. Scott Thomas (and/or his nominee(s)) as described in the Explanatory Memorandum which accompanies and forms part of this Notice of Meeting."*

Voting Exclusion - Resolution 3

The Company will disregard any votes cast in favour of this Resolution 3 by or on behalf of:

a) Mr. Scott Thomas;

b) any other person who will obtain a material benefit as a result of the issue of the securities, except a benefit solely by reason of being a holder of ordinary securities in the Company; or

c) an associate of those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or

b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

c) a Shareholder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

    (i) the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution, and

    (ii) the Shareholder votes on the Resolution in accordance with directions given by the beneficiary to the Shareholder to vote in that way.

Voting Prohibition - Resolution 3

In accordance with section 250BD of the Corporations Act, a vote on this Resolution 3 must not be cast by a person appointed as a proxy, where that person is either a member of the KMP or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:

a) the person is appointed as a proxy and the appointment specifies how the proxy is to vote; or

b) the person appointed as proxy is the Chair and the appointment does not specify how the Chair is to vote but expressly authorises the Chair to exercise the proxy even if the Resolution is connected with the remuneration of a member of the KMP.

Resolution 4. Re-election of Director – Mr. Mark Kerr

To consider and, if thought fit, to pass with or without amendment the following resolution as an **ordinary resolution**:

> *"That Mr. Mark Kerr, a Director of Cryosite Limited, who retires in accordance with clause 60.1 of the Constitution, and being eligible and offering himself, is re-elected as a Director of the Company."*

Resolution 5. Approval of Additional 10% Placement Capacity

To consider and, if thought fit, to pass with or without amendment the following resolution as a **special resolution**:

> *"That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to have the additional capacity to issue Equity Securities totaling up to 10% of the issued capital of the Company (at the time of the issue), calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Memorandum which accompanies and forms part of this Notice of Meeting."*

Voting Exclusion - Resolution 5

The Company will disregard any votes cast in favour of this Resolution 5 by or on behalf of:

a) any person who at the time approval pursuant to this Resolution 5 is sought the Company is proposing to make an issue of Equity Securities under rule 7.1A.2, any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company); or

b) an associate of that person or those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or

b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

c) a Shareholder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

   (i) the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution, and

   (ii) the Shareholder votes on the Resolution in accordance with directions given by the beneficiary to the Shareholder to vote in that way.

By order of the Board

Hamish George

Company Secretary

21 September 2026

ALL RESOLUTIONS BY POLL

In accordance with the Corporations Act and pursuant to clause 40.2.3 of the Constitution, the Chair will call a poll for each of the Resolutions proposed at the AGM.

ENTITLEMENT TO ATTEND AND VOTE

In accordance with regulation 7.11.37 of the Corporations Regulations, the Board has determined that persons who are registered holders of Shares of the Company as at 7.00pm (Melbourne time) on Tuesday, 20 October 2026 will be entitled to attend and vote at the AGM as Shareholders.

If more than one joint holder of Shares is present at the AGM (whether personally or by proxy or by attorney or by representative) and tenders a vote, only the vote of the joint holder whose name appears first in the Company's share register will be counted.

Appointment of Proxy

If you are a Shareholder entitled to attend and vote at the AGM, you may appoint an individual or a body corporate as a proxy. If a body corporate is appointed as a proxy, that body corporate must ensure that it appoints a corporate representative in accordance with section 250D of the Corporations Act to exercise its powers as proxy at the AGM. A proxy need not be a shareholder of the Company.

A Shareholder may appoint up to two proxies to attend and vote at the AGM on that Shareholder's behalf and the appointment may specify the proportion or number of votes each proxy may exercise at the AGM. If the Shareholder does not specify the proportion or number of votes to be exercised, each proxy may exercise half of the Shareholder's votes.

A proxy may vote or abstain as he or she chooses except where the appointment of the proxy directs the way the proxy is to vote on a particular resolution. To be effective, the Proxy Form (and, if the appointment is signed or authenticated by the Shareholder's attorney, the authority under which it was signed or authenticated or a certified copy of the authority) must be received at the Share Registry of the Company by no later than 11.00am (Melbourne time) on Tuesday, 20 October 2026 (being 48 hours before the AGM).

To vote by proxy:

1. Please lodge the Proxy Form online at https://investor.automic.com.au/#/loginsah by following the instructions:
    a. Login to the Automic website using the holding details as shown on the Proxy Form.
    b. Click on 'View Meetings' – 'Vote'.

To use the online lodgement facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown on the front of the Proxy Form.

2. Please complete and sign your attached Proxy Form, and deliver it to the Company's share registry, Automic Group:
    a. by post to: Automic, GPO Box 5193, Sydney NSW 2001; or
    b. by email to: meetings@automicgroup.com.au.

If you have any enquiries, please contact our Share Registry on, 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

To be valid, a proxy form must be received by the Company in the manner stipulated above. The Company reserves the right to declare invalid any proxy not received in this manner.

Power of Attorney

A Proxy Form and the original power of attorney (if any) under which the Proxy Form is signed (or a certified copy of that power of attorney or other authority) must be received by the Company no later than 11.00am

(Melbourne time) on Tuesday, 20 October 2026, being 48 hours before the AGM.

Corporate Representatives

A body corporate which is a Shareholder, or which has been appointed as a proxy, is entitled to appoint any person to act as its representative at the AGM. The appointment of the representative must comply with the requirements under section 250D of the Corporations Act. The representative should bring to the AGM a properly executed letter or other document confirming its authority to act as the body corporate's representative. Further information can be found at https://www.automicgroup.com.au/investor-services/how-do-i-appoint-a-corporate-representative.

IMPORTANT: If you appoint the Chair as your proxy, or the Chair becomes your proxy by default, and you do not direct your proxy how to vote on Resolution 1 then by submitting the proxy form you will be expressly authorising the Chair to exercise your proxy on the relevant resolution, even though the resolutions are connected, directly or indirectly, with the remuneration of the KMP.

SHAREHOLDER QUESTIONS – SUBMITTED PRIOR TO THE MEETING

Shareholders who are unable to attend the Meeting or who may prefer to register questions in advance of the Meeting are invited to do so by emailing the Company Secretary at hamish.george@bio101.com.

This includes any questions for the Chair or the Auditor. To allow time to collate questions and prepare answers, please submit any questions by 5:00pm (Melbourne time) on Thursday, 15 October 2026 (being no later than the fifth business day before the AGM is held).

Questions will be collated and, during the AGM, the Chair will seek to address as many of the more frequently raised topics as possible. However, there may not be sufficient time available at the AGM to address all topics raised. Please note that individual responses will not be sent to Shareholders.

CONDUCT OF MEETING

Cryosite is committed to ensuring that its shareholder meetings are conducted in a manner which provides those shareholders (or their proxy holders) who attend the meeting with the opportunity to participate in the business of the meeting in an orderly fashion and to ask questions about and comment on matters relevant to the business of the meeting or about the Company generally.

Cryosite will not allow conduct at any shareholder meeting which is discourteous to those who are present at the meeting, or which in any way disrupts or interferes with the proper conduct of the meeting. The Chair will exercise his powers as the Chair to ensure that the meeting is conducted in an orderly and timely fashion, in the interests of all attending shareholders.

ENCLOSURES

Enclosed are the following documents:

- Proxy Form to be completed if you would like to be represented at the AGM by a proxy, noting that Shareholders are encouraged to use the online voting facility that can be accessed on Cryosite's Share Registry's website at https://investor.automic.com.au/#/loginsah to ensure the timely and cost-effective receipt of your proxy.

EXPLANATORY MEMORANDUM

This Explanatory Memorandum has been prepared to provide Shareholders with information that is reasonably required by Shareholders to decide how to vote upon the resolutions and in relation to the business to be conducted at the Company's AGM to be held on Thursday, 22 October 2026.

Subject to the abstentions noted below and the following paragraph, the Directors unanimously recommend Shareholders vote in favour of all Resolutions

The Chair intends to vote all available undirected proxies in favour of each Resolution.

Resolution 1, relating to the Remuneration Report, is advisory only and does not bind the Directors or the Company.

Resolutions 2, 3 and 4 are ordinary resolutions, which require a simple majority of votes cast by Shareholders present and entitled to vote on the Resolutions to be in favour of those Resolutions to pass.

Resolution 5 is a special resolution, which requires at least 75% votes cast by Shareholders present and entitled to vote on the Resolutions to be in favour of those Resolutions to pass.

Resolution 1: Adoption of Remuneration Report

1.1. General

Section 250R(2) of the Corporations Act requires that the Remuneration Report of the Company be put to the vote of Shareholders for adoption by way of a non–binding vote.

Broadly, the Remuneration Report details the remuneration policy for the Company which:

a) discusses the Company's policy in relation to remuneration of the KMP;

b) discusses the relationship between the Board's remuneration policy and the Company's performance;

c) details any performance conditions attached to KMP remuneration; and

d) sets out remuneration details for each KMP.

Shareholders can view the full Remuneration Report in the Annual Report which is available on the Company's website at https://investorhub.cryosite.com/announcements

Following consideration of the Remuneration Report, the Chair of the Meeting will give Shareholders a reasonable opportunity to ask questions about, or make comments on, the Remuneration Report.

A resolution that the Remuneration Report be adopted will then be put to the vote.

The vote on Resolution 1 is advisory only and does not bind the Directors of the Company. However, the Board will take the outcome of the vote into account in setting the remuneration policy for future years.

1.2. Voting exclusion statement

In accordance with section 250R of the Corporations Act, the Company will disregard any vote cast on this Resolution 1:

a) in any capacity by, or on behalf of, a member of the KMP whose remuneration details are included in the Remuneration Report; or

b) a Closely Related Party of such member,

unless the vote is cast as a proxy for a person entitled to vote:

a) and the proxy form specifies how the proxy is to vote; or

b) the proxy is the Chair of the meeting and the appointment of the Chair as proxy:

   (i) does not specify the way the proxy is to vote on the Resolution; and

   (ii) which expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a member of the KMP.

1.3. Directors' Recommendation:

Noting that each Director has a personal interest in their own remuneration from the Company as set out in the Remuneration Report, the Directors unanimously recommend that Shareholders vote in favour of adopting the Remuneration Report.

Resolution 2: Issue of Options – Mr. Andrew Kerr

2.1. General

Resolution 2 seeks approval of the Shareholders to grant securities to Mr. Andrew Kerr (and/or his nominee(s)).

Resolution 2 is an ordinary resolution.

ASX Listing Rule 10.11 provides that a listed company must not issue, or agree to issue, equity securities to a related party (including a director of the company), or certain other persons in a position of influence, without first obtaining shareholder approval.

Accordingly, the Company seeks Shareholder approval for the grant of securities (options) to Mr. Andrew Kerr as part of his remuneration package.

If Resolution 2 is not passed, the Board may be required to propose alternative remuneration structures to continue to incentivise and remunerate Mr. Andrew Kerr, which may not be as cash efficient for the Company.

2.2. Technical information required by ASX Listing Rule 10.13

ASX Listing Rule 10.13 requires the following information in relation to Resolution 2 to be provided:

The name of the person who will be issued securities	Mr. Andrew Kerr (and/or his nominee(s))
Which category in ASX Listing Rules 10.11.1 to 10.11.5 the person falls within and why	Mr. Andrew Kerr falls within the category in ASX Listing Rule 10.11.1 as he is a director of the Company and therefore a 'related party'.
The number and class of securities proposed to be issued to the person	666,667 unlisted options vesting in eight tranches (Tranche 1A exercisable at $1.30, Tranche 1B exercisable at $1.30, Tranche 2A exercisable at $1.50, Tranche 2B exercisable at $1.50, Tranche 3A exercisable at $1.60, Tranche 3B exercisable at $1.60, Tranche 4A exercisable at $1.70 and Tranche 4B exercisable at $1.70) each with an expiry date of 26 February 2031. Each option will give Mr. Andrew Kerr a right to acquire one Share.
A summary of the material terms of the securities	The material terms of the options are as follows: (see table below) The options do not have any performance-based conditions. Unless otherwise determined by the Board, the options may lapse earlier than the expiry date in certain circumstances, such as if Mr. Andrew Kerr ceases employment, office or contract with the Group. The options do not carry any voting or dividend entitlements.

Tranche	Options	Exercise Price	Vesting Date	Expiry Date
1A	133,333	$1.30	01/03/2028	26/02/2031
1B	133,333	$1.30	01/03/2029	26/02/2031
2A	100,000	$1.50	01/03/2028	26/02/2031
2B	100,000	$1.50	01/03/2029	26/02/2031
3A	66,667	$1.60	01/03/2028	26/02/2031
3B	66,667	$1.60	01/03/2029	26/02/2031
4A	33,333	$1.70	01/03/2028	26/02/2031
4B	33,333	$1.70	01/03/2029	26/02/2031
TOTAL	**666,667**			

The date or dates on or by which the entity will issue the securities	As soon as practicable following the Annual General Meeting and by no later than 1 month after the date of the Annual General Meeting.
The price or other consideration the entity will receive for the issue of securities	No amount or consideration will be payable by Mr. Andrew Kerr for the issue of the options.
The purpose of the issue of securities, including the intended use of any funds raised by the issue	The options are proposed to be issued to incentivise the future performance of Mr. Andrew Kerr, to align his interests with shareholders of the Company consistently with the strategic goals and growth of the Company, and to ensure that the total remuneration paid to him is both equitable and competitive by market standards. The issue of the options is also believed by the Company to be a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations that it would if alternative cash forms of remuneration were awarded to Mr. Andrew Kerr. No funds will be raised on the issue of the options. Funds may be raised on exercise of the options, depending on whether and to what extent the options are exercised. Any funds raised on exercise of the options will be used to support the Company's ongoing operations, including for general working capital requirements and general corporate purposes.
Current total remuneration package	Mr. Andrew Kerr's remuneration package as Executive Director of the Company comprises: • Fixed remuneration of $246,080 (plus any statutory superannuation contributions); and • 1,000,000 unlisted options granted on 16 October 2025 as follows:

Tranche	Options	Exercise Price	Vesting Date	Expiry Date
1A	200,000	$0.90	01/03/2027	16/10/2030
1B	200,000	$0.90	01/03/2028	16/10/2030
2A	150,000	$1.10	01/03/2027	16/10/2030
2B	150,000	$1.10	01/03/2028	16/10/2030
3A	100,000	$1.20	01/03/2027	16/10/2030
3B	100,000	$1.20	01/03/2028	16/10/2030
4A	50,000	$1.30	01/03/2027	16/10/2030
4B	50,000	$1.30	01/03/2028	16/10/2030
TOTAL	**1,000,000**			

If the securities are issued under an agreement, a summary of any other material terms of the agreement	Not applicable.
Voting exclusion statement	The Company will disregard any votes cast in favour of this Resolution 2 by or on behalf of: a) Mr. Andrew Kerr;

	b) any other person who will obtain a material benefit as a result of the issue of the securities, except a benefit solely by reason of being a holder of ordinary securities in the Company; or c) an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution 2 by: a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or c) a Shareholder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution, and (ii) the Shareholder votes on the Resolution in accordance with directions given by the beneficiary to the Shareholder to vote in that way.
Voting prohibition statement	In accordance with section 250BD of the Corporations Act, a vote on this Resolution 2 must not be cast by a person appointed as a proxy, where that person is either a member of the KMP or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and: a) the person is appointed as a proxy and the appointment specifies how the proxy is to vote; or b) the person appointed as proxy is the Chair and the appointment does not specify how the Chair is to vote but expressly authorises the Chair to exercise the proxy even if the Resolution is connected with the remuneration of a member of the KMP.

2.3. Directors' Recommendation:

The Directors, with Mr. Andrew Kerr and Mr. Mark Kerr abstaining, recommend that Shareholders vote in favour of this Resolution.

Resolution 3: Issue of Options – Mr. Scott Thomas

3.1. General

Resolution 3 seeks approval of the Shareholders to grant securities to Mr. Scott Thomas (and/or his nominee(s)).

Resolution 3 is an ordinary resolution.

ASX Listing Rule 10.11 provides that a listed company must not issue, or agree to issue, equity securities to a related party (including a director of the company), or certain other persons in a position of influence, without first obtaining shareholder approval.

Accordingly, the Company seeks Shareholder approval for the grant of securities (options) to Mr. Scott Thomas as part of his remuneration package.

If Resolution 3 is not passed, the Board may be required to propose alternative remuneration structures to continue to incentivise and remunerate Mr. Scott Thomas, which may not be as cash efficient for the Company.

2.2. Technical information required by ASX Listing Rule 10.13

ASX Listing Rule 10.13 requires the following information in relation to Resolution 3 to be provided:

<table>
<tr><td>The name of the person who will be issued securities</td><td>Mr. Scott Thomas (and/or his nominee(s))</td></tr>
<tr><td>Which category in ASX Listing Rules 10.11.1 to 10.11.5 the person falls within and why</td><td>Mr. Scott Thomas falls within the category in ASX Listing Rule 10.11.1 as he is a director of the Company and therefore a 'related party'.</td></tr>
<tr><td>The number and class of securities proposed to be issued to the person</td><td>666,667 unlisted options vesting in eight tranches (Tranche 1A exercisable at $1.30, Tranche 1B exercisable at $1.30, Tranche 2A exercisable at $1.50, Tranche 2B exercisable at $1.50, Tranche 3A exercisable at $1.60, Tranche 3B exercisable at $1.60, Tranche 4A exercisable at $1.70 and Tranche 4B exercisable at $1.70) each with an expiry date of 26 February 2031.

Each option will give Mr. Scott Thomas a right to acquire one Share.</td></tr>
<tr><td>A summary of the material terms of the securities</td><td>The material terms of the options are as follows:
<table>
<tr><th>Tranche</th><th>Options</th><th>Exercise Price</th><th>Vesting Date</th><th>Expiry Date</th></tr>
<tr><td>1A</td><td>133,333</td><td>$1.30</td><td>01/03/2028</td><td>26/02/2031</td></tr>
<tr><td>1B</td><td>133,333</td><td>$1.30</td><td>01/03/2029</td><td>26/02/2031</td></tr>
<tr><td>2A</td><td>100,000</td><td>$1.50</td><td>01/03/2028</td><td>26/02/2031</td></tr>
<tr><td>2B</td><td>100,000</td><td>$1.50</td><td>01/03/2029</td><td>26/02/2031</td></tr>
<tr><td>3A</td><td>66,667</td><td>$1.60</td><td>01/03/2028</td><td>26/02/2031</td></tr>
<tr><td>3B</td><td>66,667</td><td>$1.60</td><td>01/03/2029</td><td>26/02/2031</td></tr>
<tr><td>4A</td><td>33,333</td><td>$1.70</td><td>01/03/2028</td><td>26/02/2031</td></tr>
<tr><td>4B</td><td>33,333</td><td>$1.70</td><td>01/03/2029</td><td>26/02/2031</td></tr>
<tr><td>TOTAL</td><td>666,667</td><td></td><td></td><td></td></tr>
</table>
The options do not have any performance-based conditions.

Unless otherwise determined by the Board, the options may lapse earlier than the expiry date in certain circumstances, such as if Mr. Scott Thomas ceases office or contract with the Group.

The options do not carry any voting or dividend entitlements.</td></tr>
</table>

The date or dates on or by which the entity will issue the securities	As soon as practicable following the Annual General Meeting and by no later than 1 month after the date of the Annual General Meeting.
The price or other consideration the entity will receive for the issue of securities	No amount or consideration will be payable by Mr. Scott Thomas for the issue of the options.
The purpose of the issue of securities, including the intended use of any funds raised by the issue	The options are proposed to be issued to incentivise the future performance of Mr. Scott Thomas, to align his interests with shareholders of the Company consistently with the strategic goals and growth of the Company, and to ensure that the total remuneration paid to him is both equitable and competitive by market standards. The issue of the options is also believed by the Company to be a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations that it would if alternative cash forms of remuneration were awarded to Mr. Scott Thomas. No funds will be raised on the issue of the options. Funds may be raised on exercise of the options, depending on whether and to what extent the options are exercised. Any funds raised on exercise of the options will be used to support the Company's ongoing operations, including for general working capital requirements and general corporate purposes.
Current total remuneration package	Mr. Scott Thomas' remuneration package as Non-Executive Director of the Company comprises a fixed remuneration of $80,000 (plus any statutory superannuation contributions).
If the securities are issued under an agreement, a summary of any other material terms of the agreement	Not applicable.
Voting exclusion statement	The Company will disregard any votes cast in favour of this Resolution 3 by or on behalf of: a) Mr. Scott Thomas; b) any other person who will obtain a material benefit as a result of the issue of the securities, except a benefit solely by reason of being a holder of ordinary securities in the Company; or c) an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution 3 by: a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

	c) a Shareholder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution, and (ii) the Shareholder votes on the Resolution in accordance with directions given by the beneficiary to the Shareholder to vote in that way.
Voting prohibition statement	In accordance with section 250BD of the Corporations Act, a vote on this Resolution 3 must not be cast by a person appointed as a proxy, where that person is either a member of the KMP or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and: a) the person is appointed as a proxy and the appointment specifies how the proxy is to vote; or b) the person appointed as proxy is the Chair and the appointment does not specify how the Chair is to vote but expressly authorises the Chair to exercise the proxy even if the Resolution is connected with the remuneration of a member of the KMP.

3.3. Directors' Recommendation:

The Directors, with Mr. Scott Thomas abstaining, recommend that Shareholders vote in favour of this Resolution.

Resolution 4: Re-election of Director – Mr. Mark Kerr

4.1. General

ASX Listing Rule 14.4 requires that the Company must hold an election of Directors at each annual general meeting.

The Constitution provides that at the close of each annual general meeting one-third of the Directors or, if their number is not a multiple of three, then the number nearest to but not more than one-third of the Directors, must retire.

Under Clause 60.2 of the Constitution, the Director(s) to retire by rotation at an annual general meeting are those Directors who have been longest in office since their last election.

Mr. Mark Kerr and Mr. Andrew Kerr were elected as a Director of the Company at the Company's annual general meeting on 22 November 2024. Mr. Scott Thomas was re-elected as a Director of the Company at the Company's annual general meeting on 22 October 2025.

Under Clause 60.3 of the Constitution, Directors elected on the same day may agree among themselves or determine by lot which of them must retire. Mr. Mark Kerr and Mr. Andrew Kerr have agreed among themselves that Mr. Mark Kerr will retire at the close of this AGM.

Under this Resolution, Mr. Mark Kerr seeks re-election as a Director of the Company at this AGM.

4.2. Biography

Mark Kerr is an experienced company director, chair and corporate adviser, with extensive experience across publicly listed and private companies and a range of sectors.

Mark is currently chair of the Company and Nido Education Limited. Mark was previously chair and a non-executive director of Think Childcare Limited from its ASX listing in 2014 until its acquisition by Busy Bees in 2021, and was managing director of Hawthorn Resources Limited until 2022.

Mark is also a director of Berkeley Consultants Pty Ltd, specialising in public relations, investor relations and reputation management.

Mark holds a Bachelor of Laws from the University of Melbourne.

4.3. Directors' Recommendation:

On the basis of Mr. Mark Kerr's skills, qualifications and experience and his contribution to the Board's activities, the Directors, with Mr. Mark Kerr abstaining, unanimously support the re-election of Mr. Mark Kerr as a Director and recommend that Shareholders vote in favour of this Resolution.

<u>Resolution 5. Approval of Additional 10% Placement Capacity</u>

5.1. General

Broadly speaking, and subject to a number of exceptions, ASX Listing Rule 7.1 restricts the Company from issuing or agreeing to issue more Equity Securities than the number calculated under that rule during a 12-month period without Shareholder approval. This is commonly referred to as the Company's 15% placement capacity. The 15% placement capacity is available to all listed entities and operates independently of the additional placement capacity available under ASX Listing Rule 7.1A.

ASX Listing Rule 7.1A provides an Eligible Entity with an additional placement capacity of up to 10% of its issued capital, calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2, provided that the Eligible Entity has obtained the requisite Shareholder approval by special resolution. There is no guarantee that the Company will issue any Equity Securities under the 10% Placement Capacity.

The Company is an Eligible Entity for these purposes (as described below). If Shareholders approve Resolution 5, the number of Equity Securities the Company may issue under the 10% Placement Capacity will be determined in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 (as set out below).

The effect of Resolution 5 will be to allow the Company to issue Equity Securities up to 10% of the Company's fully paid ordinary securities on issue under the 10% Placement Capacity during the period up to 12 months after the Meeting (refer to 10% Placement Capacity Period defined below), without prior Shareholder approval and without using the Company's 15% Placement Capacity granted under ASX Listing Rule 7.1.

If Resolution 5 is not passed, the Company will not be able to access the 10% Placement Capacity and will remain subject to the 15% Placement Capacity set out in ASX Listing Rule 7.1.

Resolution 5 is a special resolution. Accordingly, at least 75% of votes cast by Shareholders present and eligible to vote at the Meeting must be in favour of Resolution 5 for it to be passed.

5.2. ASX Listing Rule 7.1A

ASX Listing Rule 7.1A enables an Eligible Entity to seek Shareholder approval at its annual general meeting to issue Equity Securities in addition to those available to be issued under the Eligible Entity's 15% Placement Capacity.

An '**Eligible Entity'** is one that, as at the date of the relevant annual general meeting:

(a) is not included in the S&P/ASX 300 Index; and

(b) has a maximum market capitalisation of $300m or less.

The Company is an Eligible Entity as it is not included in the S&P/ASX 300 Index and at the date of this Notice of Meeting has a current market capitalisation of approximately $61.01m based on a Share price of $1.25 as at 3 September 2026.

The Equity Securities must be in the same class as an existing class of quoted Equity Securities. The Company currently has one class of quoted Equity Securities, being fully paid ordinary shares.

The exact number of Equity Securities that the Company may issue under an approval under ASX Listing Rule 7.1A will be calculated according to the following formula:

(A x D) – E

Where:

A is the number of Shares on issue at the commencement of the relevant period:

- plus the number of fully paid ordinary securities issued in the relevant period under an exception in ASX Listing Rule 7.2 other than exception 9, 16 or 17,

- plus the number of fully paid ordinary securities issued in the relevant period on the conversion of convertible securities within ASX Listing Rule 7.2 exception 9 where:

  - the convertible securities were issued or agreed to be issued before the commencement of the 12 month period; or

  - the issue of, or agreement to issue, the convertible securities was approved, or taken under these rules to have been approved, under ASX Listing Rule 7.1 or ASX Listing Rule 7.4,

- plus the number of fully paid ordinary securities issued in the relevant period under an agreement to issue securities within ASX Listing Rule 7.2 exception 16 where:

  - the agreement was entered into before the commencement of the 12 month period; or

  - the agreement or issue was approved, or taken under these rules to have been approved, under ASX Listing Rule 7.1 or ASX Listing Rule 7.4,

- plus the number of any other fully paid ordinary securities issued in the 12 month period with approval under ASX Listing Rule 7.1 or ASX Listing Rule 7.4,

- plus the number of partly paid ordinary securities that became fully paid in the 12 month period,

- less the number of fully paid ordinary securities cancelled in the 12 month period.

Note that "**A**" has the same meaning in ASX Listing Rule 7.1 when calculating an entity's 15% Placement Capacity.

D is 10%;

E is the number of Equity Securities issued or agreed to be issued under ASX Listing Rule 7.1A.2 in the relevant period that have not been subsequently approved by Shareholders under ASX Listing Rule 7.4.

"Relevant period" means the 12 month period immediately preceding the date of the issue or agreement.

5.3. Technical information required by ASX Listing Rule 7.1A

Pursuant to and in accordance with ASX Listing Rule 7.3A, the information below is provided in relation to this Resolution 5.

(a) Period for which the approval will be valid

In the event that the Company obtains shareholder approval of Resolution 5, such approval will commence on the date of this Meeting, and will cease to be valid upon the earlier of:

(i) 12 months after the date of the Meeting at which the approval is obtained;

(ii) the time and date of the Company's next annual general meeting, and

(iii) the time and date of approval by Shareholders of any transaction under ASX Listing Rules 11.1.2 (a significant change to the nature or scale of the Company's activities) or 11.2 (disposal of the Company's main undertaking),

(**10% Placement Capacity Period**).

Shareholder approval under ASX Listing Rule 7.1A does not lapse if the Company's market capitalisation subsequently exceeds $300 million or of it is included in the S&P/ASX 300 Index at some time during that period provided that the Company meets those criteria on the date of this Meeting.

(b) Minimum issue price

The minimum issue price at which each Equity Security may be issued must be for cash consideration which is not less than 75% of the VWAP of Equity Securities in that class, calculated over the 15 trading days on which trades in that class were recorded immediately before:

(i) the date on which the price at which the Equity Securities are to be issued is agreed by the Company and the recipient of the Equity Securities; or

(ii) if the Equity Securities are not issued within 10 trading days of the date in paragraph (b)(i) above, the date on which the Equity Securities are issued.

(c) Purpose of issue under 10% Placement Capacity

The Company may issue Equity Securities under the 10% Placement Capacity for cash consideration only. The Company intends to use any funds raised for expanding or accelerating the Company's existing business activities (including expenses associated with further development of the Company's existing assets and discovery of new assets), pursuing other acquisitions that have a strategic fit or will otherwise add value to Shareholders (including expenses associated with such acquisitions) and general working capital.

The Company will comply with the disclosure obligations under ASX Listing Rules 7.1A.4 and 3.10.3 upon issue of any Equity Securities.

As at the date of this Notice of Meeting, the Company has no specific plans to issue Equity Securities under ASX Listing Rule 7.1A.

(d) Risk of voting dilution

Any issue of Equity Securities under the 10% Placement Capacity will dilute the economic and voting interests of Shareholders who do not receive any Shares under the issue.

If Resolution 5 is approved by Shareholders and the Company issues the maximum number of Equity Securities available under the 10% Placement Capacity, the economic and voting dilution of existing Shares would be as shown in the table below.

Shareholders should note that there is a risk that:

(i) the market price for the Company's Equity Securities in that class may be significantly lower on the issue date than on the date of the approval under ASX Listing Rule 7.1A; and

(ii) the Equity Securities may be issued at a price that is at a discount to the market price for those Equity Securities on the date of issue of those Equity Securities, which may also have an effect on the amount of funds raised by the issue of the Equity Securities.

The table below shows the potential dilution of existing Shareholders calculated in accordance with the formula outlined in ASX Listing Rule 7.1A(2), on the basis of the current market price of Shares and the number of Equity Securities the Company will have on issue as at the date of this Notice of Meeting.

The table also shows two examples where variable "A" has increased, by 50% and 100%. Variable "A" is based on the number of ordinary securities the Company will have on issue at the date of the Meeting. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under ASX Listing Rule 7.1 that are approved at a future Shareholders' meeting; and two examples of where the issue price of ordinary securities has altered, one by a decrease by 50% and the other by an increase by 50% as against the current market price. The voting dilution impact where the number of Shares on issue (variable A in the formula) changes and the economic dilution where there are changes in the issue price of Shares issued under the 10% Placement Capacity.

Variable "A" ASX Listing Rule 7.1A.2		**Potential Dilution and Funds Raised**		
		$0.625 50% decrease in issue price	**$1.250** Issue price[b]	**$1.875** 50% increase in issue price
"A" is the number of shares on issue, [a] being	**10% voting dilution[C]**	4,880,956	4,880,956	4,880,956
48,809,563	**Funds raised**	$3,050,598	$6,101,195	$9,151,793
"A" is a 50% increase in shares on issue, being	**10% voting dilution[c]**	7,321,434	7,321,434	7,321,434
73,214,345	**Funds raised**	$4,575,897	$9,151,793	$13,727,690
"A" is a 100% increase in shares on issue, being	**10% voting dilution[c]**	9,761,913	9,761,913	9,761,913
97,619,126	**Funds raised**	$6,101,195	$12,202,391	$18,303,586

The table above uses the following assumptions:

a. The current shares on issue are the Shares on issue as at 3 September 2026.
b. The issue price set out above of $1.250 is the closing price of the Shares on the ASX on 3 September 2026.
c. The Company issues the maximum possible number of Equity Securities under the 10% Placement Capacity.
d. No options are exercised into Shares before the date of the issue of the Equity Securities.
e. The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
f. The calculations above do not show the dilution that any one particular Shareholder will be subject to by reason of placements under the 10% Placement Capacity. All Shareholders should consider the dilution caused to their own shareholding depending on their specific circumstances.
g. This table does not set out any dilution pursuant to issues approved under ASX Listing Rule 7.1.

(e) Allocation under the 10% Placement Capacity

The Company may not issue any or all the Equity Securities for which approval is given and may issue the Equity Securities progressively as the Company places the Equity Securities with investors.

The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Capacity. The identity of the allottees of Equity Securities will be determined on a case-by-case basis having regard to the factors including, but not limited to:

(i) the purpose of the issue;

(ii) alternative methods for raising funds available to the Company at that time, including, but not limited to, an entitlement issue or other offer where existing Shareholders may participate;

(iii) the effect of the issue of the Equity Securities on the control of the Company;

(iv) the circumstances of the Company, including, but not limited to, the financial position and solvency of the Company; and

(v) advice from corporate, financial, legal and broking advisers (if applicable).

The allottees of the Equity Securities to be issued under the 10% Placement Capacity have not yet been determined as at the date of this Notice. It is intended that the allottees will be suitable professional and sophisticated investors, and other investors not requiring a disclosure document under section 708 of the Corporations Act, that are known to the Company and/or introduced by third parties.

The allottees may include existing substantial shareholders and/or new shareholders, but the allottees will not be related parties of the Company.

The Company will comply with the disclosure obligations under ASX Listing Rules 7.1A.4 and 3.10.3 upon issue of any Equity Securities.

(f) Previous approval and issues under ASX Listing Rule 7.1A

The Company has previously obtained Shareholder approval under ASX Listing Rule 7.1A at its annual general meeting held on 16 October 2025.

The Company has not issued or agreed to issue any securities under its 10% Placement Capacity in the 12 months preceding the date of this Meeting pursuant to ASX Listing Rule 7.1A.2.

5.4. What will happen if Shareholders give, or do not give, approval?

If Resolution 5 is passed, the Company will be able to issue Equity Securities up to the combined 25% limit in ASX Listing Rules 7.1 and 7.1A without any further Shareholder approval.

If Resolution 5 is not passed, the Company will not be able to access the additional 10% Placement Capacity to issue Equity Securities without Shareholder approval provided for in ASX Listing Rule 7.1A, and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in ASX Listing Rule 7.1.

5.5. Voting exclusion statement

The Company will disregard any votes cast in favour of this Resolution 5 by or on behalf of:

a) any person who at the time approval pursuant to this Resolution 5 is sought the Company is proposing to make an issue of Equity Securities under rule 7.1A.2, any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company); or

b) an associate of that person or those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or

b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

c) a Shareholder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

    (i) the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution, and

    (ii) the Shareholder votes on the Resolution in accordance with directions given by the beneficiary to the Shareholder to vote in that way.

5.5. Directors' Recommendation:

The Directors unanimously recommend that Shareholders vote in favour of this Resolution.

GLOSSARY

$ means Australian dollars.

Annual General Meeting, AGM or Meeting means the annual general meeting convened by the Notice of Meeting.

ASX means ASX Limited ACN 008 624 691, or the financial market operated by ASX Limited, as the context requires.

ASX Listing Rules means the Listing Rules of ASX.

Board means the board of Directors of the Company.

Auditor means the Company's external auditor Forvis Mazars Audit & Assurance Pty Ltd.

Business Day means Monday to Friday inclusive, except recognised public holidays by the state of New South Wales.

Chair means the chairperson of the Meeting.

Closely Related Party of a member of the Key Management Personnel means:

(a) a spouse or child of the member;

(b) a child of the member's spouse;

(c) a dependent of the member or the member's spouse;

(d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealing with the Company;

(e) a company the member controls; or

(f) a person prescribed by the Corporations Regulations for the purposes of this definition.

Company means Cryosite Limited ACN 090 919 476.

Constitution means the Company's constitution, as amended or varied from time to time.

Corporations Act means the *Corporations Act 2001* (Cth).

Corporations Regulations means the *Corporations Regulations 2001* (Cth).

Director means a director of the Company.

Equity Security means:

(a) a share;

(b) a right to a share or option;

(c) an option over an issued or unissued security;

(d) a convertible security; or

(e) any security that ASX decides to classify as an equity security.

Explanatory Memorandum means the explanatory memorandum accompanying the Notice of Meeting.

Group Company means the Company each Subsidiary of the Company.

Key Management Personnel or KMP means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

Notice of Meeting means this notice of meeting including the Explanatory Memorandum and the Proxy Form.

Option has the meaning given to that term in the ASX Listing Rules.

Proxy Form means the proxy form accompanying the Notice of Meeting.

Remuneration Report means the remuneration report dealing with the remuneration of Directors and key management personnel of the Company as set out in the Director's report section of the Company's annual financial report for the year ended 30 June 2026.

Reports means the Annual Report which contains the Company's Annual Financial Report, the Directors' Report and the Independent Auditor's Report for the year ended 30 June 2026.

Resolutions means each of the resolutions set out in the Notice of Meeting, or any one of them, as the context requires.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

Share Registry means Automic Pty Ltd.

Subsidiary has the meaning given to that term in the Corporations Act.

VWAP means volume weighted average price.

cryosite

Cryosite Limited | ABN 86 090 919 476

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Your proxy voting instruction must be received by **11:00am (AEDT) on Tuesday, 20 October 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS
The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: **https://investor.automic.com.au/#/home** Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY
If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING
Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS
You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY
You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS
Individual: Where the holding is in one name, the Shareholder must sign.
Joint holding: Where the holding is in more than one name, all Shareholders should sign.
Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.
Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.
Email Address: Please provide your email address in the space provided.
By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES
If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at https://automicgroup.com.au.

Lodging your Proxy Voting Form:

Online
Use your computer or smartphone to appoint a proxy at
https://portal.automic.com.au/investor/home or scan the QR code below using your smartphone
Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.

BY MAIL:
Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:
Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:
meetings@automicgroup.com.au

BY FACSIMILE:
+61 2 8583 3040

All enquiries to Automic:
WEBSITE:
https://automicgroup.com.au

PHONE:
1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

STEP 1 - How to vote

APPOINT A PROXY:

I/We being a Shareholder entitled to attend and vote at the Annual General Meeting of Cryosite Limited, to be held at **11:00am (AEDT) on Thursday, 22 October 2026 at Thomsons, Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000** hereby:

Appoint the Chair of the Meeting (Chair) to vote in accordance with the following directions (or if no directions have been given, and subject to the relevant laws, as the Chair sees fit) at this meeting and at any adjournment thereof.

Please note: If you are not appointing the Chair of the Meeting as your proxy, please write in the box provided below the name of the person or body corporate you are appointing as your proxy. If the person so named is absent from the meeting, or if no person is named, the Chair will act on your behalf.

The Chair intends to vote undirected proxies in favour of all Resolutions in which the Chair is entitled to vote.
Unless indicated otherwise by marking the "for", "against" or "abstain" box you will be authorising the Chair to vote in accordance with the Chair's voting intention.

AUTHORITY FOR CHAIR TO VOTE UNDIRECTED PROXIES ON REMUNERATION RELATED RESOLUTIONS
Where I/we have appointed the Chair as my/our proxy (or where the Chair becomes my/our proxy by default), I/we expressly authorise the Chair to exercise my/our proxy on Resolutions 1, 2 and 3 (except where I/we have indicated a different voting intention below) even though Resolutions 1, 2 and 3 are connected directly or indirectly with the remuneration of a member of the Key Management Personnel, which includes the Chair.

STEP 2 - Your voting direction

	Resolutions	For	Against	Abstain
1	Adoption of Remuneration Report			
2	Issue of Options – Mr. Andrew Kerr			
3	Issue of Options – Mr. Scott Thomas			
4	Re-election of Director – Mr. Mark Kerr			
5	Approval of Additional 10% Placement Capacity			

Please note: If you mark the abstain box for a particular Resolution, you are directing your proxy not to vote on that Resolution and your votes will not be counted in computing the required majority on a poll.

STEP 3 – Signatures and contact details

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary

Contact Name:

Email Address:

Contact Daytime Telephone

Date (DD/MM/YY)

/ /

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).

AUTOMIC

CTE